MX2012007590A - Composicion para mejorar la funcion cerebral y metodo para mejorar la funcion cerebral. - Google Patents
Composicion para mejorar la funcion cerebral y metodo para mejorar la funcion cerebral.Info
- Publication number
- MX2012007590A MX2012007590A MX2012007590A MX2012007590A MX2012007590A MX 2012007590 A MX2012007590 A MX 2012007590A MX 2012007590 A MX2012007590 A MX 2012007590A MX 2012007590 A MX2012007590 A MX 2012007590A MX 2012007590 A MX2012007590 A MX 2012007590A
- Authority
- MX
- Mexico
- Prior art keywords
- pro
- thr
- val
- brain function
- gln
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se provee una composición para mejorar la función cerebral, que se puede tomar por vía oral a una dosis baja, y un método para la misma; la composición para mejorar la función cerebral contiene, como el ingrediente activo, X-Pro-Pro-Leu-Thr-Gln-Thr-Pro-VaI-Val- VaI-Pro-Pro-Phe-Leu-Gln-ProGlu-Y (en donde X es nulo o representa Ile o Asn-lle; y Y es nulo o representa VaI-Met), X-Val-Val-Val-Pro-Pro-Phe-Leu-Gln-Pro-GIu-Y (en donde X está ausente o representa Thr-Gln-Thr-Pro, Pro-Leu-Thr-GIn-Thr-Pro, Leu-Th r-Gln Thr-Pro o Pro; y Y está ausente o representa Val-Met), o una sal del mismo; el método para mejorar la función cerebral comprende administrar dicho péptido o una sal del mismo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009297022 | 2009-12-28 | ||
JP2010147156 | 2010-06-29 | ||
PCT/JP2010/065483 WO2011080947A1 (ja) | 2009-12-28 | 2010-09-09 | 脳機能改善用組成物および脳機能を改善する方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012007590A true MX2012007590A (es) | 2012-07-30 |
Family
ID=44226368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012007590A MX2012007590A (es) | 2009-12-28 | 2010-09-09 | Composicion para mejorar la funcion cerebral y metodo para mejorar la funcion cerebral. |
Country Status (19)
Country | Link |
---|---|
US (1) | US8569241B2 (es) |
EP (1) | EP2520308B1 (es) |
JP (2) | JP4824841B2 (es) |
KR (1) | KR20120116453A (es) |
CN (1) | CN102686234B (es) |
AU (1) | AU2010337738B2 (es) |
BR (1) | BR112012015984A2 (es) |
CA (1) | CA2784132C (es) |
DK (1) | DK2520308T3 (es) |
ES (1) | ES2581242T3 (es) |
HK (1) | HK1171379A1 (es) |
MX (1) | MX2012007590A (es) |
MY (2) | MY160372A (es) |
NZ (1) | NZ601142A (es) |
RU (1) | RU2501808C1 (es) |
SG (1) | SG181982A1 (es) |
TW (1) | TWI461208B (es) |
WO (1) | WO2011080947A1 (es) |
ZA (1) | ZA201204262B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012036191A1 (ja) * | 2010-09-16 | 2012-03-22 | カルピス株式会社 | 脳機能改善用組成物および脳機能を改善する方法 |
JP5686680B2 (ja) * | 2011-06-24 | 2015-03-18 | カルピス株式会社 | 乳酸菌発酵によるカゼイン由来ペプチドの製造方法 |
JP5718741B2 (ja) * | 2011-06-24 | 2015-05-13 | カルピス株式会社 | 脳機能改善用ペプチドの酵素的製造方法 |
CN104013953A (zh) * | 2014-06-24 | 2014-09-03 | 罗浩铭 | 具有治疗老年性痴呆及改善学习记忆新用途的14肽化合物 |
CN108137650B (zh) * | 2015-11-16 | 2022-04-08 | 麒麟控股株式会社 | 肽组合物及其制造方法 |
WO2019168149A1 (ja) | 2018-03-02 | 2019-09-06 | 一般財団法人糧食研究会 | 認知機能を改善するペプチド |
AU2019366076A1 (en) | 2018-10-26 | 2021-06-10 | Asahi Group Holdings, Ltd. | Anti-obesity agent, pollakiuria improving agent, and autonomic nervous activity regulator |
JP7407124B2 (ja) * | 2018-11-16 | 2023-12-28 | アサヒグループホールディングス株式会社 | 言語力等を改善するための組成物および方法 |
JPWO2022202985A1 (es) * | 2021-03-24 | 2022-09-29 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0331298A (ja) * | 1989-06-28 | 1991-02-12 | Ajinomoto Co Inc | プロリルエンドペプチターゼ阻害ペプチド |
JP3488722B2 (ja) * | 1992-03-04 | 2004-01-19 | カルピス株式会社 | カルシウム吸収促進活性剤及びその製造法 |
RU2104702C1 (ru) * | 1996-10-16 | 1998-02-20 | Общество с ограниченной ответственностью "Клиника Института биорегуляции и геронтологии" | Способ получения из животного сырья комплекса биологически активных полипептидов, нормализующих функции головного мозга, фармакологическая композиция и ее применение |
GB9912852D0 (en) | 1999-06-02 | 1999-08-04 | Regen Therapeutics Plc | Peptides |
JP3898389B2 (ja) | 1999-08-27 | 2007-03-28 | 独立行政法人科学技術振興機構 | 抗健忘作用を有するペプチド |
JP4633876B2 (ja) * | 1999-11-11 | 2011-02-16 | カルピス株式会社 | トリペプチドの製造方法 |
GB0001825D0 (en) * | 2000-01-26 | 2000-03-22 | Regen Therapeutics Plc | Peptides |
GB0029777D0 (en) * | 2000-12-06 | 2001-01-17 | Regen Therapeutics Plc | Peptides |
US8017168B2 (en) | 2006-11-02 | 2011-09-13 | The Coca-Cola Company | High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith |
JP5188731B2 (ja) * | 2007-03-02 | 2013-04-24 | 雪印メグミルク株式会社 | ペプチド |
WO2009096490A1 (ja) * | 2008-01-29 | 2009-08-06 | National University Corporation Nagoya University | ペプチド固定化用溶液及びその利用 |
DK2270133T3 (en) * | 2008-04-22 | 2015-09-07 | Corporación Alimentaria Peñasanta Capsa | Method of obtaining a new strain of Bifidobacterium bidifum with effect against infection with Helicobacter pylori |
WO2010071132A1 (ja) | 2008-12-15 | 2010-06-24 | カルピス株式会社 | 皮膚老化抑制ペプチド |
EP2258208A1 (en) * | 2009-06-02 | 2010-12-08 | University of Limerick | Protein Product With Modified Antigenicity |
-
2010
- 2010-09-09 MX MX2012007590A patent/MX2012007590A/es active IP Right Grant
- 2010-09-09 BR BR112012015984-4A patent/BR112012015984A2/pt not_active IP Right Cessation
- 2010-09-09 CA CA2784132A patent/CA2784132C/en active Active
- 2010-09-09 EP EP10840806.3A patent/EP2520308B1/en active Active
- 2010-09-09 NZ NZ601142A patent/NZ601142A/xx unknown
- 2010-09-09 KR KR1020127019725A patent/KR20120116453A/ko not_active Application Discontinuation
- 2010-09-09 MY MYPI2012002927A patent/MY160372A/en unknown
- 2010-09-09 SG SG2012048245A patent/SG181982A1/en unknown
- 2010-09-09 RU RU2012132469/10A patent/RU2501808C1/ru active
- 2010-09-09 ES ES10840806.3T patent/ES2581242T3/es active Active
- 2010-09-09 MY MYPI2014000040A patent/MY165041A/en unknown
- 2010-09-09 DK DK10840806.3T patent/DK2520308T3/en active
- 2010-09-09 AU AU2010337738A patent/AU2010337738B2/en active Active
- 2010-09-09 JP JP2011520254A patent/JP4824841B2/ja active Active
- 2010-09-09 WO PCT/JP2010/065483 patent/WO2011080947A1/ja active Application Filing
- 2010-09-09 CN CN201080059886.7A patent/CN102686234B/zh active Active
- 2010-09-16 TW TW099131410A patent/TWI461208B/zh active
-
2011
- 2011-05-30 JP JP2011119960A patent/JP4989775B2/ja active Active
-
2012
- 2012-06-11 ZA ZA2012/04262A patent/ZA201204262B/en unknown
- 2012-06-25 US US13/532,394 patent/US8569241B2/en active Active
- 2012-11-28 HK HK12112227.6A patent/HK1171379A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP2520308A4 (en) | 2013-07-03 |
US8569241B2 (en) | 2013-10-29 |
TW201121563A (en) | 2011-07-01 |
HK1171379A1 (en) | 2013-03-28 |
EP2520308B1 (en) | 2016-06-22 |
ES2581242T3 (es) | 2016-09-02 |
KR20120116453A (ko) | 2012-10-22 |
BR112012015984A2 (pt) | 2018-05-29 |
CA2784132C (en) | 2015-05-05 |
AU2010337738B2 (en) | 2013-09-19 |
CN102686234A (zh) | 2012-09-19 |
AU2010337738A2 (en) | 2012-07-05 |
ZA201204262B (en) | 2013-08-28 |
JP4989775B2 (ja) | 2012-08-01 |
WO2011080947A1 (ja) | 2011-07-07 |
US20120277160A1 (en) | 2012-11-01 |
AU2010337738A1 (en) | 2012-07-12 |
CA2784132A1 (en) | 2011-07-07 |
JP2012031139A (ja) | 2012-02-16 |
SG181982A1 (en) | 2012-08-30 |
EP2520308A1 (en) | 2012-11-07 |
RU2501808C1 (ru) | 2013-12-20 |
CN102686234B (zh) | 2015-06-17 |
JPWO2011080947A1 (ja) | 2013-05-09 |
MY160372A (en) | 2017-03-15 |
DK2520308T3 (en) | 2016-09-26 |
JP4824841B2 (ja) | 2011-11-30 |
TWI461208B (zh) | 2014-11-21 |
NZ601142A (en) | 2013-11-29 |
MY165041A (en) | 2018-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012007590A (es) | Composicion para mejorar la funcion cerebral y metodo para mejorar la funcion cerebral. | |
AU2012259422A8 (en) | Solid forms of a pharmaceutically active substance | |
EA026667B9 (ru) | Фармацевтическая композиция для лечения вируса гепатита с | |
EA201390885A1 (ru) | Азаиндолы в качестве противовирусных агентов против респираторного синцитиального вируса | |
MY183312A (en) | Pharmaceutical formulation | |
PH12016502103A1 (en) | Novel disubstituted 1,2, 4-triazine compound | |
WO2013142817A3 (en) | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | |
TN2012000152A1 (en) | Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes | |
UA103332C2 (ru) | Фармацевтическая композиция, которая содержит непептидный активный агент с первичной или вторичной аминогруппой | |
IN2014KN00948A (es) | ||
BR112012026767A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal | |
HK1166788A1 (es) | ||
GEP20156263B (en) | Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for production and usage thereof | |
MX2013010552A (es) | Compuestos de guanidina. | |
NZ602510A (en) | Treatment of lupus nephritis using laquinimod | |
IN2012DN01855A (es) | ||
MX2012003324A (es) | Compuesto de glicina. | |
WO2011126250A3 (ko) | Pde5 억제제를 함유하는 피부 주름 개선용 조성물 | |
WO2012168885A9 (en) | Bisacodyl and its analogues as drugs for use in the treatment of cancer | |
MX2014009850A (es) | Spiro [2.4] heptanos para aplicaciones relacionadas con el tratamiento de infecciones de flaviviridae. | |
WO2011159137A3 (ko) | 신규한 티오우레아 또는 우레아 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 aids 예방 또는 치료용 약학 조성물 | |
MX2014003701A (es) | Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio. | |
TN2012000105A1 (en) | Spirolactam derivatives and uses of same | |
TN2014000060A1 (en) | Benzothiazolone compound | |
MY193996A (en) | Tripeptide compound, preparation method therefor, and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |